CJC-1295 / Ipamorelin: What It Is, Where to Get It Prescribed, and What It Costs

This is a blend of two peptides that both act on the pituitary, the gland at the base of the brain that releases growth hormone, through different doors. CJC-1295 is a modified version of growth-hormone-releasing hormone (GHRH), the signal the hypothalamus sends to tell the pituitary to release. Ipamorelin is a five-amino-acid peptide that mimics ghrelin at a separate receptor. Neither contains growth hormone; both ask your own pituitary to release what it already makes, in the pulsed pattern it always has.

CJC-1295 exists in two forms. The version in the 2006 human trials carried a "drug affinity complex" (DAC), a tag that binds the peptide to albumin and keeps it circulating for about a week. The version in compounded blends, including this one, is CJC-1295 without DAC, also called modified GRF (1-29): the same 29-amino-acid GHRH fragment with four stabilising substitutions but no albumin tag, so it lasts roughly half an hour. That is why it is dosed daily and paired with ipamorelin for one clean pulse rather than a week-long elevation.

Ipamorelin was developed by Novo Nordisk in the 1990s as the first ghrelin-receptor agonist that released growth hormone without meaningfully raising cortisol, prolactin or ACTH; the 1998 paper in the European Journal of Endocrinology titled it "the first selective growth hormone secretagogue."

It is not growth hormone, and not a substitute for growth hormone therapy in a diagnosed deficiency, which is a separate, FDA-approved treatment. It is not an anabolic steroid and does not suppress testosterone. It is not a weight-loss medication: ipamorelin's receptor is the one ghrelin uses to signal hunger. And it is not fast.

CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, raising cyclic AMP and driving both release of stored growth hormone and synthesis of more. In a 2006 study in the American Journal of Physiology, once-daily CJC-1295 normalised growth in mice engineered to lack GHRH entirely. The substitutions that distinguish it from sermorelin protect it from the enzyme DPP-IV.

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary cells and hypothalamic neurons, triggering release directly and, at the hypothalamus, reducing somatostatin, the brake signal. The 1998 characterisation reported that in animal models it released growth hormone with potency similar to GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH, cortisol or prolactin at doses well above the releasing dose.

The two act on different receptors in the same cell, and one also removes the somatostatin brake, so giving both produces a larger pulse than either alone; the classes have been described as more than additive since the early 1990s. One dose of both, on an empty stomach, is intended to produce a single pulse resembling the body's own nocturnal pulse.

The reason a physician reaches for secretagogues rather than growth hormone itself is that the pituitary keeps control. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism gave healthy adults the DAC form of CJC-1295 and sampled blood every ten minutes: the pulsatile pattern was preserved, with more hormone per pulse rather than a flat elevation. The finding is about how the pituitary responds to GHRH stimulation and applies to the daily-dosed form.

Growth hormone is short-lived in blood; most of what it does, it does by prompting the liver to make insulin-like growth factor 1 (IGF-1), which acts on muscle, bone, connective tissue and fat. The 2006 study reported IGF-1 staying elevated for more than a week after a single injection of the DAC form. IGF-1 is also the marker a physician can measure: baseline tells them where your axis is starting, a follow-up whether the pituitary is responding and the dose is right. Fasting glucose is often checked too, because growth hormone opposes insulin.

In the 2006 Journal of Clinical Endocrinology and Metabolism trial, CJC-1295 with DAC given to healthy adults produced dose-dependent increases in growth hormone and IGF-1 that persisted for days and was described as well tolerated. For ipamorelin, a 1999 paper in Pharmaceutical Research modelled the growth hormone response to intravenous doses in human volunteers and reported dose-dependent release with a half-life measured in hours.

The rationale is physiological. The largest growth hormone pulse of the day occurs during slow-wave sleep, and a 2000 study in JAMA found slow-wave sleep and growth hormone secretion declining together in healthy men from early adulthood. Prescribers reason that restoring a nocturnal pulse may travel with deeper sleep, and patients frequently report it, but no published trial of this blend has sleep as an endpoint.

Growth hormone's effects on lean mass, fat distribution and bone are established from growth hormone itself and from tesamorelin, a different GHRH analogue with trial data in a specific population. For this blend's components the work is animal: a 1999 study in Growth Hormone and IGF Research reported ipamorelin increasing longitudinal bone growth in rats, and a 2000 paper in the Journal of Endocrinology reported increased bone mineral content in adult female rats. There are no human trials of the blend for body composition.

Ipamorelin's other line of development was post-operative ileus. Rodent work in the Journal of Pharmacology and Experimental Therapeutics in 2009 reported improved gastric emptying, and a 2014 randomised, placebo-controlled phase 2 study in the International Journal of Colorectal Disease of intravenous ipamorelin in bowel-resection patients did not show a significant difference from placebo on its recovery endpoints. Different route, dose and population, but it is the largest human study of ipamorelin.

There are no randomised controlled trials of the CJC-1295 / Ipamorelin blend in humans. The human evidence is the 2006 healthy-adult trials of the DAC form of CJC-1295, the 1999 study of intravenous ipamorelin, and the 2014 post-operative ileus trial. Each shows the peptide raises growth hormone as intended; none measured sleep, recovery or body composition in the people typically prescribed the blend. The honest framing is "known to raise growth hormone and IGF-1 in humans; benefits beyond that are inferred from physiology and clinical experience," not "proven for sleep or body composition."

• It does not establish that the blend improves sleep, recovery or body composition; those outcomes have not been measured in a trial.
• It does not establish an effect size or a timeline. Timelines below are prescriber experience.
• It does not establish long-term safety with continuous use over years, which is one reason physicians monitor IGF-1.
• It does not establish efficacy for any condition as an FDA-approved treatment. Neither component is approved for anything.

The first thing most people describe is sleep: falling asleep faster or waking less, sometimes within the first few nights. Some notice nothing at all, which is normal; growth hormone pulses are not something you feel.

This is the window in which IGF-1 changes would show on bloodwork, and where prescribers describe recovery and body-composition shifts beginning, if they happen. Two vials cover it. Any change is described as gradual and dependent on sleep, protein and training, none of which the peptide replaces.

There is no withdrawal and no rebound described, because the pituitary was never suppressed. Sleep and recovery generally drift back toward baseline over weeks; whether any change in composition persists depends on whether training and sleep habits changed alongside it.

The directions are written in millilitres and insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe, and that draw contains both peptides in a fixed ratio, so you never adjust one against the other.

Subcutaneous means into the fat layer, not the muscle; abdomen and thigh are the usual sites, rotated. The empty-stomach instruction is not a formality: glucose and fatty acids after a meal blunt the growth hormone pulse. Many prescribers direct it at bedtime so the induced pulse lines up with the body's own slow-wave-sleep pulse; your directions will say.

20 doses at once daily Monday through Friday is exactly four weeks, which is why refills run on a 28-day cycle. The weekday-only pattern is how the reviewed directions are written; do not change it without asking your physician. One vial per fill, always.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label.

Ipamorelin on its own triggers a pulse; adding CJC-1295 enlarges it. The single agent is described as gentler and is a reasonable first step when a physician wants to see how the axis responds. The blend is the more common prescription because the two are more than additive.

Sermorelin is GHRH (1-29) without the stabilising substitutions, so it produces a briefer signal, and it has the longest human track record of any GHRH analogue. Ipamorelin + Sermorelin is the equivalent blend built on it. CJC-1295 / Ipamorelin / Sermorelin stacks both with the secretagogue; a step up in price, not in evidence.

Tesamorelin is the one GHRH analogue with randomised human trials and an FDA-approved brand, for excess abdominal fat in a specific population; compounded tesamorelin is not that approved product, but the molecule's evidence is stronger. If visceral fat is the target a physician may prefer it; if sleep and recovery are, this blend is the more usual choice.

Identical medication. The pepti Pen is a pre-filled cartridge in a reusable click-dial injector, dosed in clicks rather than drawn from a vial with a syringe. It costs more and it removes the draw step. Neither is clinically better.